{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:22:10Z","timestamp":1790976130805,"version":"4.1.0"},"reference-count":56,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The specific targeting of critical signaling molecules may provide efficient therapies for T-cell acute lymphoblastic leukemia (T-ALL). However, target identification and drug development are limited by insufficient numbers of primary T-ALL cells and by their high rate of spontaneous apoptosis. We established a human interleukin-7 (IL-7)\u2013dependent T-ALL cell line, TAIL7, that maintains several biologic and signaling properties of its parental leukemia cells. TAIL7 cells are pre\u2013T-ALL cells that proliferate in response to IL-7 and IL-4. IL-7 stimulation of TAIL7 cells prevents spontaneous in vitro apoptosis and induces cell activation and cell cycle progression. The signaling events triggered by IL-7 include down-regulation of p27kip1 and hyperphosphorylation of retinoblastoma protein (Rb). Stimulation of TAIL7 cells by IL-7 leads to phosphorylation of Janus kinase 3 (JAK3), signal transducer and activator of transcription 5 (STAT5), Akt\/PKB (protein kinase B), and extracellular-regulated kinase 1 and 2 (Erk1\/2). Importantly, specific blockade of JAK3 by its inhibitor WHI-P131 abrogates the IL-7\u2013mediated proliferation and survival of TAIL7 cells, suggesting that activation of JAK3 is critical for IL-7 responsiveness by these cells. Because TAIL7 cells seem to be a biologic surrogate for primary leukemia T cells, this cell line constitutes a valuable tool for the study of the signaling pathways implicated in T-ALL. Exploitation of this cell line should allow the identification of molecular targets and promote the rational design and validation of antileukemia signaling inhibitors.<\/jats:p>","DOI":"10.1182\/blood-2002-12-3861","type":"journal-article","created":{"date-parts":[[2003,11,18]],"date-time":"2003-11-18T01:14:02Z","timestamp":1069118042000},"page":"1891-1900","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":36,"title":["IL-7\u2013dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL"],"prefix":"10.1182","volume":"103","author":[{"given":"Joao T.","family":"Barata","sequence":"first","affiliation":[{"name":"From the Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and the Unit of Tumor Biology, Institute of Molecular Medicine, University of Lisbon Medical School, Lisbon, Portugal."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki A.","family":"Boussiotis","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and the Unit of Tumor Biology, Institute of Molecular Medicine, University of Lisbon Medical School, Lisbon, Portugal."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Yunes","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and the Unit of Tumor Biology, Institute of Molecular Medicine, University of Lisbon Medical School, Lisbon, Portugal."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo A.","family":"Ferrando","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and the Unit of Tumor Biology, Institute of Molecular Medicine, University of Lisbon Medical School, Lisbon, Portugal."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Moreau","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and the Unit of Tumor Biology, Institute of Molecular Medicine, University of Lisbon Medical School, Lisbon, Portugal."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Pedro","family":"Veiga","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and the Unit of Tumor Biology, Institute of Molecular Medicine, University of Lisbon Medical School, Lisbon, Portugal."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Sallan","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and the Unit of Tumor Biology, Institute of Molecular Medicine, University of Lisbon Medical School, Lisbon, Portugal."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Thomas","family":"Look","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and the Unit of Tumor Biology, Institute of Molecular Medicine, University of Lisbon Medical School, Lisbon, Portugal."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee M.","family":"Nadler","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and the Unit of Tumor Biology, Institute of Molecular Medicine, University of Lisbon Medical School, Lisbon, Portugal."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo A.","family":"Cardoso","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and the Unit of Tumor Biology, Institute of Molecular Medicine, University of Lisbon Medical School, Lisbon, Portugal."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021218162227500_REF1","doi-asserted-by":"crossref","unstructured":"Sawyers CL. Rational therapeutic intervention in cancer: kinases as drug targets. Curr Opin Genet Dev. 2002;12: 111-115.","DOI":"10.1016\/S0959-437X(01)00273-8"},{"key":"2020021218162227500_REF2","doi-asserted-by":"crossref","unstructured":"Gibbs JB. Anticancer drug targets: growth factors and growth factor signaling. J Clin Invest. 2000; 105: 9-13.","DOI":"10.1172\/JCI9084"},{"key":"2020021218162227500_REF3","doi-asserted-by":"crossref","unstructured":"Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene. 2000;19: 6680-6686.","DOI":"10.1038\/sj.onc.1204091"},{"key":"2020021218162227500_REF4","doi-asserted-by":"crossref","unstructured":"Barata JT, Cardoso AA, Nadler LM, Boussiotis VA. Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1). Blood. 2001;98: 1524-1531.","DOI":"10.1182\/blood.V98.5.1524"},{"key":"2020021218162227500_REF5","doi-asserted-by":"crossref","unstructured":"von Freeden-Jeffry U, Solvason N, Howard M, Murray R. The earliest T lineage-committed cells depend on IL-7 for Bcl-2 expression and normal cell cycle progression. Immunity. 1997;7: 147-154.","DOI":"10.1016\/S1074-7613(00)80517-8"},{"key":"2020021218162227500_REF6","doi-asserted-by":"crossref","unstructured":"Peschon JJ, Morrissey PJ, Grabstein KH, et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med. 1994;180: 1955-1960.","DOI":"10.1084\/jem.180.5.1955"},{"key":"2020021218162227500_REF7","doi-asserted-by":"crossref","unstructured":"von Freeden-Jeffry U, Vieira P, Lucian LA, McNeil T, Burdach SE, Murray R. Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J Exp Med. 1995;181: 1519-1526.","DOI":"10.1084\/jem.181.4.1519"},{"key":"2020021218162227500_REF8","doi-asserted-by":"crossref","unstructured":"Rich BE, Campos-Torres J, Tepper RI, Moreadith RW, Leder P. Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice. J Exp Med. 1993;177: 305-316.","DOI":"10.1084\/jem.177.2.305"},{"key":"2020021218162227500_REF9","doi-asserted-by":"crossref","unstructured":"Touw I, Pouwels K, van Agthoven T, et al. Interleukin-7 is a growth factor of precursor B and T acute lymphoblastic leukemia. Blood. 1990;75: 2097-2101.","DOI":"10.1182\/blood.V75.11.2097.2097"},{"key":"2020021218162227500_REF10","doi-asserted-by":"crossref","unstructured":"Makrynikola V, Kabral A, Bradstock K. Effects of interleukin 7 on the growth of clonogenic cells in T-cell acute lymphoblastic leukaemia. Leuk Res. 1991;15: 879-882.","DOI":"10.1016\/0145-2126(91)90162-M"},{"key":"2020021218162227500_REF11","doi-asserted-by":"crossref","unstructured":"Henney CS. Interleukin 7: effects on early events in lymphopoiesis. Immunol Today. 1989;10: 170-173.","DOI":"10.1016\/0167-5699(89)90175-8"},{"key":"2020021218162227500_REF12","doi-asserted-by":"crossref","unstructured":"Cardoso AA, Schultze JL, Boussiotis VA, et al. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood. 1996; 88: 41-48.","DOI":"10.1182\/blood.V88.1.41.41"},{"key":"2020021218162227500_REF13","doi-asserted-by":"crossref","unstructured":"Pongers-Willemse MJ, Seriu T, Stolz F, et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13: 110-118.","DOI":"10.1038\/sj.leu.2401245"},{"key":"2020021218162227500_REF14","unstructured":"Aubin J, Davi F, Nguyen-Salomon F, et al. Description of a novel FR1 IgH PCR strategy and its comparison with three other strategies for the detection of clonality in B cell malignancies. Leukemia. 1995;9: 471-479."},{"key":"2020021218162227500_REF15","doi-asserted-by":"crossref","unstructured":"Lefranc MP. IMGT, the international ImMunoGeneTics database. Nucleic Acids Res. 2001;29: 207-209.","DOI":"10.1093\/nar\/29.1.207"},{"key":"2020021218162227500_REF16","doi-asserted-by":"crossref","unstructured":"Boussiotis VA, Freeman GJ, Berezovskaya A, Barber DL, Nadler LM. Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1. Science. 1997;278: 124-128.","DOI":"10.1126\/science.278.5335.124"},{"key":"2020021218162227500_REF17","unstructured":"Sudbeck EA, Liu XP, Narla RK, et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res. 1999;5: 1569-1582."},{"key":"2020021218162227500_REF18","doi-asserted-by":"crossref","unstructured":"Ferrando A, Neuberg D, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1: 75-87.","DOI":"10.1016\/S1535-6108(02)00018-1"},{"key":"2020021218162227500_REF19","doi-asserted-by":"crossref","unstructured":"Meshinchi S, Woods WG, Stirewalt DL, et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001;97: 89-94.","DOI":"10.1182\/blood.V97.1.89"},{"key":"2020021218162227500_REF20","doi-asserted-by":"crossref","unstructured":"Karawajew L, Ruppert V, Wuchter C, et al. Inhibition of in vitro spontaneous apoptosis by IL-7 correlates with bcl-2 up-regulation, cortical\/mature immunophenotype, and better early cytoreduction of childhood T-cell acute lymphoblastic leukemia. Blood. 2000;96: 297-306.","DOI":"10.1182\/blood.V96.1.297"},{"key":"2020021218162227500_REF21","doi-asserted-by":"crossref","unstructured":"Uckun FM, Gaynon PS, Sensel MG, et al. Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study. J Clin Oncol. 1997;15: 2214-2221.","DOI":"10.1200\/JCO.1997.15.6.2214"},{"key":"2020021218162227500_REF22","unstructured":"Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9: 1783-1786."},{"key":"2020021218162227500_REF23","unstructured":"Garand R, Voisin S, Papin S, et al. Characteristics of pro-T ALL subgroups: comparison with late T-ALL. The Groupe d'Etude Immunologique des Leucemies. Leukemia. 1993;7: 161-167."},{"key":"2020021218162227500_REF24","doi-asserted-by":"crossref","unstructured":"Kawano S, Tatsumi E, Yoneda N, Tani A, Nakamura F. Expression pattern of CD45 RA\/RO isoformic antigens in T-lineage neoplasms. Am J Hematol. 1995;49: 6-14.","DOI":"10.1002\/ajh.2830490103"},{"key":"2020021218162227500_REF25","doi-asserted-by":"crossref","unstructured":"Sharfe N, Dadi HK, Roifman CM. JAK3 protein tyrosine kinase mediates interleukin-7-induced activation of phosphatidylinositol-3\u2032 kinase. Blood. 1995;86: 2077-2085.","DOI":"10.1182\/blood.V86.6.2077.bloodjournal8662077"},{"key":"2020021218162227500_REF26","doi-asserted-by":"crossref","unstructured":"Wuchter C, Ruppert V, Schrappe M, Dorken B, Ludwig WD, Karawajew L. In vitro susceptibility to dexamethasone- and doxorubicin-induced apoptotic cell death in context of maturation stage, responsiveness to interleukin 7, and early cytoreduction in vivo in childhood T-cell acute lymphoblastic leukemia. Blood. 2002;99: 4109-4115.","DOI":"10.1182\/blood.V99.11.4109"},{"key":"2020021218162227500_REF27","doi-asserted-by":"crossref","unstructured":"Styczynski J, Pieters R, Huismans DR, Schuurhuis GJ, Wysocki M, Veerman AJ. In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia. Br J Haematol. 2000;110: 813-818.","DOI":"10.1046\/j.1365-2141.2000.02211.x"},{"key":"2020021218162227500_REF28","doi-asserted-by":"crossref","unstructured":"Baer R, Hwang LY, Bash RO. Transcription factors of the bHLH and LIM families: synergistic mediators of T cell acute leukemia? Curr Top Microbiol Immunol. 1997;220: 55-65.","DOI":"10.1007\/978-3-642-60479-9_4"},{"key":"2020021218162227500_REF29","doi-asserted-by":"crossref","unstructured":"Masters JR. Human cancer cell lines: fact and fantasy. Nat Rev Mol Cell Biol. 2000;1: 233-236.","DOI":"10.1038\/35043102"},{"key":"2020021218162227500_","doi-asserted-by":"crossref","unstructured":"Schneider U, Schwenk HU, Bornkamm G. Characterization of EBV-genome negative \u201cnull\u201d and \u201cT\u201d cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int J Cancer. 1977;19: 621-626.","DOI":"10.1002\/ijc.2910190505"},{"key":"2020021218162227500_REF31","unstructured":"Minowada J, Onuma T, Moore GE. Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. J Natl Cancer Inst. 1972;49: 891-895."},{"key":"2020021218162227500_REF32","doi-asserted-by":"crossref","unstructured":"Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol. 2002;128: 255-266.","DOI":"10.1046\/j.1365-2249.2002.01777.x"},{"key":"2020021218162227500_REF33","doi-asserted-by":"crossref","unstructured":"Blankenberg FG, Storrs RW, Naumovski L, Goralski T, Spielman D. Detection of apoptotic cell death by proton nuclear magnetic resonance spectroscopy. Blood. 1996;87: 1951-1956.","DOI":"10.1182\/blood.V87.5.1951.1951"},{"key":"2020021218162227500_REF34","unstructured":"Smith SD, Shatsky M, Cohen PS, Warnke R, Link MP, Glader BE. Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines. Cancer Res. 1984;44: 5657-5660."},{"key":"2020021218162227500_REF35","doi-asserted-by":"crossref","unstructured":"Amarante-Mendes JG, Chammas R, Abrahamsohn P, Patel PC, Potworowski EF, Macedo MS. Cloning of a thymic stromal cell capable of protecting thymocytes from apoptosis. Cell Immunol. 1995;161: 173-180.","DOI":"10.1006\/cimm.1995.1024"},{"key":"2020021218162227500_REF36","unstructured":"Conroy LA, Alexander DR. The role of intracellular signalling pathways regulating thymocyte and leukemic T cell apoptosis. Leukemia. 1996;10: 1422-1435."},{"key":"2020021218162227500_REF37","doi-asserted-by":"crossref","unstructured":"Dibirdik I, Langlie MC, Ledbetter JA, et al. Engagement of interleukin-7 receptor stimulates tyrosine phosphorylation, phosphoinositide turnover, and clonal proliferation of human T-lineage acute lymphoblastic leukemia cells. Blood. 1991; 78: 564-570.","DOI":"10.1182\/blood.V78.3.564.564"},{"key":"2020021218162227500_REF38","doi-asserted-by":"crossref","unstructured":"Funk PE, Stephan RP, Witte PL. Vascular cell adhesion molecule 1-positive reticular cells express interleukin-7 and stem cell factor in the bone marrow. Blood. 1995;86: 2661-2671.","DOI":"10.1182\/blood.V86.7.2661.2661"},{"key":"2020021218162227500_REF39","doi-asserted-by":"crossref","unstructured":"Young JC, Gishizky ML, Witte ON. Hyperexpression of interleukin-7 is not necessary or sufficient for transformation of a pre-B lymphoid cell line. Mol Cell Biol. 1991;11: 854-863.","DOI":"10.1128\/MCB.11.2.854"},{"key":"2020021218162227500_","unstructured":"Chen SC, Redenius D, Young JC, Schwartz RC. Synergy of IL-7 and v-Ha-ras in the in vitro neoplastic progression of murine pre-B cells. Oncogene. 1993;8: 2119-2125."},{"key":"2020021218162227500_REF41","doi-asserted-by":"crossref","unstructured":"Smith KS, Rhee JW, Cleary ML. Transformation of bone marrow B-cell progenitors by E2a-Hlf requires coexpression of Bcl-2. Mol Cell Biol. 2002; 22: 7678-7687.","DOI":"10.1128\/MCB.22.21.7678-7688.2002"},{"key":"2020021218162227500_REF42","doi-asserted-by":"crossref","unstructured":"Kim K, Lee CK, Sayers TJ, Muegge K, Durum SK. The trophic action of IL-7 on pro-T cells: inhibition of apoptosis of pro-T1, -T2, and -T3 cells correlates with Bcl-2 and Bax levels and is independent of Fas and p53 pathways. J Immunol. 1998;160: 5735-5741.","DOI":"10.4049\/jimmunol.160.12.5735"},{"key":"2020021218162227500_REF43","doi-asserted-by":"crossref","unstructured":"Hare KJ, Jenkinson EJ, Anderson G. An essential role for the IL-7 receptor during intrathymic expansion of the positively selected neonatal T cell repertoire. J Immunol. 2000;165: 2410-2414.","DOI":"10.4049\/jimmunol.165.5.2410"},{"key":"2020021218162227500_REF44","doi-asserted-by":"crossref","unstructured":"Akashi K, Kondo M, Weissman IL. Role of interleukin-7 in T-cell development from hematopoietic stem cells. Immunol Rev. 1998;165: 13-28.","DOI":"10.1111\/j.1600-065X.1998.tb01226.x"},{"key":"2020021218162227500_REF45","doi-asserted-by":"crossref","unstructured":"Puel A, Ziegler SF, Buckley RH, Leonard WJ. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet. 1998; 20: 394-397.","DOI":"10.1038\/3877"},{"key":"2020021218162227500_REF46","doi-asserted-by":"crossref","unstructured":"Roifman CM, Zhang J, Chitayat D, Sharfe N. A partial deficiency of interleukin-7R alpha is sufficient to abrogate T-cell development and cause severe combined immunodeficiency. Blood. 2000;96: 2803-2807.","DOI":"10.1182\/blood.V96.8.2803"},{"key":"2020021218162227500_REF47","doi-asserted-by":"crossref","unstructured":"Gescher A. Modulators of signal transduction as cancer chemotherapeutic agents\u2014novel mechanisms and toxicities. Toxicol Lett. 1995;82-83: 159-165.","DOI":"10.1016\/0378-4274(95)03475-7"},{"key":"2020021218162227500_REF48","doi-asserted-by":"crossref","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344: 783-792.","DOI":"10.1056\/NEJM200103153441101"},{"key":"2020021218162227500_REF49","doi-asserted-by":"crossref","unstructured":"Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997;278: 1309-1312.","DOI":"10.1126\/science.278.5341.1309"},{"key":"2020021218162227500_","doi-asserted-by":"crossref","unstructured":"Carron C, Cormier F, Janin A, et al. TEL-JAK2 transgenic mice develop T-cell leukemia. Blood. 2000;95: 3891-3899.","DOI":"10.1182\/blood.V95.12.3891"},{"key":"2020021218162227500_REF51","doi-asserted-by":"crossref","unstructured":"Gouilleux-Gruart V, Gouilleux F, Desaint C, et al. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood. 1996;87: 1692-1697.","DOI":"10.1182\/blood.V87.5.1692.1692"},{"key":"2020021218162227500_REF52","doi-asserted-by":"crossref","unstructured":"Sugawara T, Moriguchi T, Nishida E, Takahama Y. Differential roles of ERK and p38 MAP kinase pathways in positive and negative selection of T lymphocytes. Immunity. 1998;9: 565-574.","DOI":"10.1016\/S1074-7613(00)80639-1"},{"key":"2020021218162227500_REF53","doi-asserted-by":"crossref","unstructured":"Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase\/AKT pathway. Proc Natl Acad Sci U S A. 1999;96: 4240-4245.","DOI":"10.1073\/pnas.96.8.4240"},{"key":"2020021218162227500_REF54","unstructured":"Krasilnikov MA. Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation. Biochemistry (Mosc). 2000;65: 59-67."},{"key":"2020021218162227500_REF55","doi-asserted-by":"crossref","unstructured":"Gonzalez J, Harris T, Childs G, Prystowsky MB. Rapamycin blocks IL-2-driven T cell cycle progression while preserving T cell survival. Blood Cells Mol Dis. 2001;27: 572-585.","DOI":"10.1006\/bcmd.2001.0420"},{"key":"2020021218162227500_REF56","doi-asserted-by":"crossref","unstructured":"Bonetta L. Leukemia case triggers tighter genetherapy controls. Nat Med. 2002;8: 1189.","DOI":"10.1038\/nm1102-1189"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/5\/1891\/1696377\/zh800504001891.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/5\/1891\/1696377\/zh800504001891.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T12:05:04Z","timestamp":1704974704000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/103\/5\/1891\/18246\/IL7dependent-human-leukemia-Tcell-line-as-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3,1]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,3,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-12-3861","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3,1]]}}}